Confronting multidrug-resistant Acinetobacter baumannii: A review

International Journal of Antimicrobial Agents

Volumn 37, Issue 2, 2011, Pages 102-109

  Neonakis, Ioannis K ^a,b   Spandidos, Demetrios A ^b   Petinaki, Efthimia ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Acinetobacter baumannii; Colistin; Minocycline; Peptides; Rifampicin; Tigecycline

Indexed keywords

ALYTESERIN 1C; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA DEFENSIN 2; BUFORIN II; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; MEROPENEM; MINOCYCLINE; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SULBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

EID: 78751581939     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.10.014     Document Type: Short Survey

References (141)

1. J. Vila, and J. Pachon Therapeutic options for Acinetobacter baumannii infections Expert Opin Pharmacother 9 2008 587 599
2. H. Giamarellou, A. Antoniadou, and K. Kanellakopoulou Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 32 2008 106 119
3. P.E. Fournier, and H. Richet The epidemiology and control of Acinetobacter baumannii in health care facilities Clin Infect Dis 42 2006 692 699
4. A.P. Zavascki, C.G. Carvalhaes, R.C. Picao, and A.C. Gales Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy Expert Rev Anti Infect Ther 8 2010 71 93
5. R. Maviglia, R. Nestorini, and M. Pennisi Role of old antibiotics in multidrug resistant bacterial infections Curr Drug Targets 10 2009 895 905
6. D.L. Paterson The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species Clin Infect Dis 43 Suppl. 2 2006 S43 S48
7. K.S. Ko, J.Y. Suh, K.T. Kwon, S.I. Jung, K.H. Park, and C.I. Kang High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea J Antimicrob Chemother 60 2007 1163 1167
8. Y. Doi, S. Husain, B.A. Potoski, K.R. McCurry, and D.L. Paterson Extensively drug-resistant Acinetobacter baumannii Emerg Infect Dis 15 2009 980 982
9. J.Y. Fagon, J. Chastre, A.J. Hance, P. Montravers, A. Novara, and C. Gibert Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay Am J Med 94 1993 281 288
10. J. Rello, V. Ausina, M. Ricart, J. Castella, and G. Prats Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia Chest 104 1993 1230 1235
11. A.Y. Peleg, H. Seifert, and D.L. Paterson Acinetobacter baumannii: emergence of a successful pathogen Clin Microbiol Rev 21 2008 538 582
12. L.C. McDonald Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment Clin Infect Dis 42 Suppl. 2 2006 S65 S71
13. M. Bassetti, E. Righi, S. Esposito, N. Petrosillo, and L. Nicolini Drug treatment for multidrug-resistant Acinetobacter baumannii infections Future Microbiol 3 2008 649 660
14. M.E. Falagas, E.G. Mourtzoukou, M. Polemis, and A.C. Vatopoulos Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications Clin Microbiol Infect 13 2007 816 819
15. M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, and D.E. Karageorgopoulos Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2010 194 199
16. H. Kallel, L. Hergafi, M. Bahloul, A. Hakim, H. Dammak, and H. Chelly Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study Intensive Care Med 33 2007 1162 1167
17. K.P. Holloway, N.G. Rouphael, J.B. Wells, M.D. King, and H.M. Blumberg Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit Ann Pharmacother 40 2006 1939 1945
18. A.S. Michalopoulos, S. Tsiodras, K. Rellos, S. Mentzelopoulos, and M.E. Falagas Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic Clin Microbiol Infect 11 2005 115 121
19. A.S. Levin, A.A. Barone, J. Penco, M.V. Santos, I.S. Marinho, and E.A. Arruda Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis 28 1999 1008 1011
20. F. Timurkaynak, F. Can, O.K. Azap, M. Demirbilek, H. Arslan, and S.O. Karaman In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units Int J Antimicrob Agents 27 2006 224 228
21. T.Y. Tan, L.S. Ng, E. Tan, and G. Huang In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates J Antimicrob Chemother 60 2007 421 423
22. J.J. Rahal Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species Clin Infect Dis 43 Suppl. 2 2006 S95 S99
23. J. Yoon, C. Urban, C. Terzian, N. Mariano, and J.J. Rahal In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 48 2004 753 757
24. G.A. Pankuch, G. Lin, H. Seifert, and P.C. Appelbaum Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii Antimicrob Agents Chemother 52 2008 333 336
25. I. Galani, F. Kontopidou, M. Souli, P.D. Rekatsina, E. Koratzanis, and J. Deliolanis Colistin susceptibility testing by Etest and disk diffusion methods Int J Antimicrob Agents 31 2008 434 439
26. T.Y. Tan, and L.S. Ng Comparison of three standardized disc susceptibility testing methods for colistin J Antimicrob Chemother 58 2006 864 867
27. J.R. Lo-Ten-Foe, A.M. de Smet, B.M. Diederen, J.A. Kluytmans, and P.H. van Keulen Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains Antimicrob Agents Chemother 51 2007 3726 3730
28. H. Giamarellou, and G. Poulakou Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69 2009 1879 1901
29. T.Y. Tan, and S.Y. Ng Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin Clin Microbiol Infect 13 2007 541 544
30. N.P. Mortensen, J.D. Fowlkes, C.J. Sullivan, D.P. Allison, N.B. Larsen, and S. Molin Effects of colistin on surface ultrastructure and nanomechanics of Pseudomonas aeruginosa cells Langmuir 25 2009 3728 3733
31. M.L. Young, M. Bains, A. Bell, and R.E. Hancock Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques Antimicrob Agents Chemother 36 1992 2566 2568
32. J.A. Bengoechea, and M. Skurnik Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia Mol Microbiol 37 2000 67 80
33. M.E. Falagas, P.I. Rafailidis, D.K. Matthaiou, S. Virtzili, D. Nikita, and A. Michalopoulos Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients Int J Antimicrob Agents 32 2008 450 454
34. H. Giamarellou Colistin: the loss of the last frontier? APUA Newslett 25 2007 5
35. P. Beno, V. Krcmery, and A. Demitrovicova Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin Clin Microbiol Infect 12 2006 497 498
36. M. Souli, I. Galani, and H. Giamarellou Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe Euro Surveill 13 2008 pii: 19045
37. A.C. Gales, R.N. Jones, and H.S. Sader Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) Clin Microbiol Infect 12 2006 315 321
38. M. Souli, F.V. Kontopidou, E. Koratzanis, A. Antoniadou, E. Giannitsioti, and P. Evangelopoulou In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals Antimicrob Agents Chemother 50 2006 3166 3169
39. J. Li, C.R. Rayner, R.L. Nation, R.J. Owen, D. Spelman, and K.E. Tan Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 50 2006 2946 2950
40. J.S. Hawley, C.K. Murray, and J.H. Jorgensen Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy Antimicrob Agents Chemother 52 2008 351 352
41. W. Yau, R.J. Owen, A. Poudyal, J.M. Bell, J.D. Turnidge, and H.H. Yu Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme J Infect 58 2009 138 144
42. M.E. Falagas, and S.K. Kasiakou Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections Clin Infect Dis 40 2005 1333 1341
43. J. Li, K. Coulthard, R. Milne, R.L. Nation, S. Conway, and D. Peckham Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis J Antimicrob Chemother 52 2003 987 992
44. J. Li, C.R. Rayner, R.L. Nation, R. Deans, R. Boots, and N. Widdecombe Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration Antimicrob Agents Chemother 49 2005 4814 4815
45. R.L. Nation, and J. Li Colistin in the 21st century Curr Opin Infect Dis 22 2009 535 543
46. E. Wolinsky, and J.D. Hines Neurotoxic and nephrotoxic effects of colistin in patients with renal disease N Engl J Med 266 1962 759 762
47. J. Koch-Weser, V.W. Sidel, E.B. Federman, P. Kanarek, D.C. Finer, and A.E. Eaton Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy Ann Intern Med 72 1970 857 868
48. S.P. Conway, M.N. Pond, A. Watson, C. Etherington, H.L. Robey, and M.H. Goldman Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis Thorax 52 1997 987 993
49. M.E. Falagas, M. Rizos, I.A. Bliziotis, K. Rellos, S.K. Kasiakou, and A. Michalopoulos Toxicity after prolonged (more than four weeks) administration of intravenous colistin BMC Infect Dis 5 2005 1
50. S.K. Kasiakou, A. Michalopoulos, E.S. Soteriades, G. Samonis, G.J. Sermaides, and M.E. Falagas Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis Antimicrob Agents Chemother 49 2005 3136 3146
51. R. Reina, E. Estenssoro, G. Saenz, H.S. Canales, R. Gonzalvo, and G. Vidal Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study Intensive Care Med 31 2005 1058 1065
52. A. Stein, and D. Raoult Colistin: an antimicrobial for the 21st century? Clin Infect Dis 35 2002 901 902
53. J.D. Hartzell, R. Neff, J. Ake, R. Howard, S. Olson, and K. Paolino Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center Clin Infect Dis 48 2009 1724 1728
54. J. Bergeron, M. Ammirati, D. Danley, L. James, M. Norcia, and J. Retsema Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection Antimicrob Agents Chemother 40 1996 2226 2228
55. N. Kasbekar Tigecycline: a new glycylcycline antimicrobial agent Am J Health Syst Pharm 63 2006 1235 1243
56. M. Bhattacharya, A. Parakh, and M. Narang Tigecycline J Postgrad Med 55 2009 65 68
57. M. Casal, F. Rodriguez, B. Johnson, E. Garduno, F. Tubau, and R.O. de Lejarazu Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother 64 2009 69 72
58. L.F. Canigia, and C. Bantar Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar? J Antimicrob Chemother 62 2008 1463 1464
59. R. Hope, M. Warner, S. Mushtaq, M.E. Ward, T. Parsons, and D.M. Livermore Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines J Antimicrob Chemother 56 2005 1042 1046
60. P.J. Petersen, and P.A. Bradford Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates Antimicrob Agents Chemother 49 2005 3910 3918
61. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
62. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing. Version 9.1 March 2010. Birmingham, UK: BSAC; 2010. p. 32. http://www.bsac.org.uk/Resources/BSAC/Version-9.1-March-2010- final.pdf [accessed 29 October 2010].
63. R.R. Reinert, D.E. Low, F. Rossi, X. Zhang, C. Wattal, and M.J. Dowzicky Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline J Antimicrob Chemother 60 2007 1018 1029
64. M.W. Garrison, R. Mutters, and M.J. Dowzicky In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007 Diagn Microbiol Infect Dis 65 2009 288 299
65. D.C. Draghi, S. Tench, M.J. Dowzicky, and D.F. Sahm Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance Chemotherapy 54 2008 91 100
66. D.J. Hoban, S.K. Bouchillon, and M.J. Dowzicky Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial Diagn Microbiol Infect Dis 57 2007 423 428
67. K. Vasilev, G. Reshedko, R. Orasan, M. Sanchez, J. Teras, and T. Babinchak A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae J Antimicrob Chemother 62 Suppl. 1 2008 i29 i40
68. N.C. Gordon, and D.W. Wareham A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline J Antimicrob Chemother 63 2009 775 780
69. D.E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M.E. Falagas Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence J Antimicrob Chemother 62 2008 45 55
70. G. Poulakou, F.V. Kontopidou, E. Paramythiotou, M. Kompoti, M. Katsiari, and E. Mainas Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens J Infect 58 2009 273 284
71. J.C. Gallagher, and H.M. Rouse Tigecycline for the treatment of Acinetobacter infections: a case series Ann Pharmacother 42 2008 1188 1194
72. K.B. Anthony, N.O. Fishman, D.R. Linkin, L.B. Gasink, P.H. Edelstein, and E. Lautenbach Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline Clin Infect Dis 46 2008 567 570
73. J.J. Schafer, D.A. Goff, K.B. Stevenson, and J.E. Mangino Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii Pharmacotherapy 27 2007 980 987
74. G.E. Reid, S.A. Grim, C.A. Aldeza, W.M. Janda, and N.M. Clark Rapid development of Acinetobacter baumannii resistance to tigecycline Pharmacotherapy 27 2007 1198 1201
75. A.Y. Peleg, B.A. Potoski, R. Rea, J. Adams, J. Sethi, and B. Capitano Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report J Antimicrob Chemother 59 2007 128 131
76. L. Principe, S. D'Arezzo, A. Capone, N. Petrosillo, and P. Visca In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii Ann Clin Microbiol Antimicrob 8 2009 18
77. J.M. Entenza, and P. Moreillon Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies Int J Antimicrob Agents 34 2009 8.e1-9
78. T.P. Lim, T.Y. Tan, W. Lee, S. Sasikala, T.T. Tan, and L.Y. Hsu In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore J Antibiot (Tokyo) 62 2009 675 679
79. P.J. Petersen, P. Labthavikul, C.H. Jones, and P.A. Bradford In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis J Antimicrob Chemother 57 2006 573 576
80. L.A. Arroyo, I. Mateos, V. Gonzalez, and J. Aznar In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group Antimicrob Agents Chemother 53 2009 1295 1296
81. M. Dizbay, D.K. Tozlu, M.Y. Cirak, Y. Isik, K. Ozdemir, and D. Arman In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii J Antibiot (Tokyo) 63 2010 51 53
82. T. Leclerc, J.P. Perez, B. Debien, P. Clapson, and B. Lenoir Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination [in French] Ann Fr Anesth Reanim 26 2007 1056 1058
83. F.S. Taccone, H. Rodriguez-Villalobos, D. De Backer, V. De Moor, J. Deviere, and J.L. Vincent Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline Eur J Clin Microbiol Infect Dis 25 2006 257 260
84. J.Y. Choi, C.O. Kim, Y.S. Park, H.J. Yoon, S.Y. Shin, and Y.K. Kim Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia Yonsei Med J 47 2006 63 69
85. J.M. Cisneros, M.J. Reyes, J. Pachon, B. Becerril, F.J. Caballero, and J.L. Garcia-Garmendia Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features Clin Infect Dis 22 1996 1026 1032
86. T.K. Jellison, P.S. McKinnon, and M.J. Rybak Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam Pharmacotherapy 21 2001 142 148
87. A.Y. Peleg Optimizing therapy for Acinetobacter baumannii Semin Respir Crit Care Med 28 2007 662 671
88. R. Smolyakov, A. Borer, K. Riesenberg, F. Schlaeffer, M. Alkan, and A. Porath Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment J Hosp Infect 54 2003 32 38
89. A.S. Levin, C.E. Levy, A.E. Manrique, E.A. Medeiros, and S.F. Costa Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam Int J Antimicrob Agents 21 2003 58 62
90. H.M. Lode Rational antibiotic therapy and the position of ampicillin/sulbactam Int J Antimicrob Agents 32 2008 10 28
91. X. Corbella, J. Ariza, C. Ardanuy, M. Vuelta, F. Tubau, and M. Sora Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii J Antimicrob Chemother 42 1998 793 802
92. G.C. Wood, S.D. Hanes, M.A. Croce, T.C. Fabian, and B.A. Boucher Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia Clin Infect Dis 34 2002 1425 1430
93. M.S. Oliveira, G.V. Prado, S.F. Costa, R.S. Grinbaum, and A.S. Levin Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61 2008 1369 1375
94. F. Fernandez-Cuenca, A. Pascual, A. Ribera, J. Vila, G. Bou, and J.M. Cisneros Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000) Enferm Infecc Microbiol Clin 22 2004 267 271 [in Spanish]
95. S.C. Yang, W.J. Chang, Y.H. Chang, Y.S. Tsai, T.P. Yang, and C.W. Juan Prevalence of antibiotics resistance and OXA carbapenemases genes in multidrug-resistant Acinetobacter baumannii isolates in central Taiwan Eur J Clin Microbiol Infect Dis 29 2010 601 604
96. W. Tong, R. Wang, D. Chai, Z. Li, and F. Pei In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. Int J Antimicrob Agents 28 2006 454 456
97. J.Y. Song, S.Y. Kee, I.S. Hwang, Y.B. Seo, H.W. Jeong, and W.J. Kim In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J Antimicrob Chemother 60 2007 317 322
98. E. Savov, D. Chankova, R. Vatcheva, and N. Dinev In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin Int J Antimicrob Agents 20 2002 390 392
99. W.C. Ko, H.C. Lee, S.R. Chiang, J.J. Yan, J.J. Wu, and C.L. Lu In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain J Antimicrob Chemother 53 2004 393 395
100. M.D. Appleman, H. Belzberg, D.M. Citron, P.N. Heseltine, A.E. Yellin, and J. Murray In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak Antimicrob Agents Chemother 44 2000 1035 1040
101. C.R. Kiffer, J.L. Sampaio, S. Sinto, C.P. Oplustil, P.C. Koga, and A.C. Arruda In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii Diagn Microbiol Infect Dis 52 2005 317 322
102. E.J. Giamarellos-Bourboulis, E. Xirouchaki, and H. Giamarellou Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii Diagn Microbiol Infect Dis 40 2001 117 120
103. M. Wolff, M.L. Joly-Guillou, R. Farinotti, and C. Carbon In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model Antimicrob Agents Chemother 43 1999 1406 1411
104. A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, and J. Ayats Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii Antimicrob Agents Chemother 46 2002 1946 1952
105. M.F. Tripodi, E. Durante-Mangoni, R. Fortunato, R. Utili, and R. Zarrilli Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases Int J Antimicrob Agents 30 2007 537 540
106. M.E. Pachon-Ibanez, F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam J Antimicrob Chemother 58 2006 689 692
107. C.H. Rodriguez, A. De Ambrosio, M. Bajuk, M. Spinozzi, M. Nastro, and K. Bombicino In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones J Infect Dev Ctries 4 2010 164 167
108. A. Pantopoulou, E.J. Giamarellos-Bourboulis, M. Raftogannis, T. Tsaganos, I. Dontas, and P. Koutoukas Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin Int J Antimicrob Agents 29 2007 51 55
109. M. Bassetti, E. Repetto, E. Righi, S. Boni, M. Diverio, and M.P. Molinari Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections J Antimicrob Chemother 61 2008 417 420
110. N. Petrosillo, P. Chinello, M.F. Proietti, L. Cecchini, M. Masala, and C. Franchi Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events Clin Microbiol Infect 11 2005 682 683
111. S. Motaouakkil, B. Charra, A. Hachimi, H. Nejmi, A. Benslama, and N. Elmdaghri Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii J Infect 53 2006 274 278
112. J.Y. Song, J. Lee, J.Y. Heo, J.Y. Noh, W.J. Kim, and H.J. Cheong Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii Int J Antimicrob Agents 32 2008 281 284
113. E. Bishburg, and K. Bishburg Minocycline - an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii Int J Antimicrob Agents 34 2009 395 401
114. M.E. Griffith, H.C. Yun, L.L. Horvath, and C.K. Murray Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex Infect Dis Clin Pract 16 2008 16 19
115. G.C. Wood, S.D. Hanes, B.A. Boucher, M.A. Croce, and T.C. Fabian Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia Intensive Care Med 29 2003 2072 2076
116. M.E. Falagas, A.C. Kastoris, A.M. Kapaskelis, and D.E. Karageorgopoulos Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review Lancet Infect Dis 10 2010 43 50
117. M.E. Falagas, A.C. Kastoris, D.E. Karageorgopoulos, and P.I. Rafailidis Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies Int J Antimicrob Agents 34 2009 111 120
118. M.E. Falagas, M.D. Kanellopoulou, D.E. Karageorgopoulos, G. Dimopoulos, P.I. Rafailidis, and N.D. Skarmoutsou Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin Eur J Clin Microbiol Infect Dis 27 2008 439 443
119. R. Dobrewski, E. Savov, A.T. Bernards, M. van den Barselaar, P. Nordmann, and P.J. van den Broek Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital Clin Microbiol Infect 12 2006 1135 1137
120. L. Martinez-Martinez, G. Rodriguez, A. Pascual, A.I. Suarez, and E.J. Perea In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii J Antimicrob Chemother 38 1996 1107 1108
121. S.K. Kasiakou, K.R. Lawrence, N. Choulis, and M.E. Falagas Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters Drugs 65 2005 2499 2511
122. J. Fishbain, and A.Y. Peleg Treatment of Acinetobacter infections Clin Infect Dis 51 2010 79 84
123. C. Li, J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients J Clin Pharmacol 46 2006 1171 1178
124. S. Jaruratanasirikul, S. Sriwiriyajan, and J. Punyo Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection Antimicrob Agents Chemother 49 2005 1337 1339
125. S.K. Kasiakou, G.J. Sermaides, A. Michalopoulos, E.S. Soteriades, and M.E. Falagas Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials Lancet Infect Dis 5 2005 581 589
126. P.I. Vergidis, and M.E. Falagas New antibiotic agents for bloodstream infections Int J Antimicrob Agents 32 Suppl. 1 2008 S60 S65
127. S.F. Barbuceanu, G.L. Almajan, I. Saramet, C. Draghici, A.I. Tarcomnicu, and G. Bancescu Synthesis, characterization and evaluation of antibacterial activity of some thiazolo[3,2-b][1,2,4]triazole incorporating diphenylsulfone moieties Eur J Med Chem 44 2009 4752 4757
128. G.L. Almajan, S.F. Barbuceanu, E.R. Almajan, C. Draghici, and G. Saramet Synthesis, characterization and antibacterial activity of some triazole Mannich bases carrying diphenylsulfone moieties Eur J Med Chem 44 2009 3083 3089
129. V. Duraipandiyan, and S. Ignacimuthu Antibacterial and antifungal activity of flindersine isolated from the traditional medicinal plant, Toddalia asiatica (L.) Lam J Ethnopharmacol 123 2009 494 498
130. H.T. Tan, R.A. Rahman, S.H. Gan, A.S. Halim, S.A. Hassan, and S.A. Sulaiman The antibacterial properties of Malaysian tualang honey against wound and enteric microorganisms in comparison to manuka honey BMC Complement Altern Med 9 2009 34
131. M.D. Aytemir, and B. Ozcelik A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities Eur J Med Chem 45 2010 4089 4095
132. W.R. Schwan, C. Dunek, M. Gebhardt, K. Engelbrecht, T. Klett, and A. Monte Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity Ann Clin Microbiol Antimicrob 9 2010 4
133. J.M. Conlon, A. Demandt, P.F. Nielsen, J. Leprince, H. Vaudry, and D.C. Woodhams The alyteserins: two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes obstetricans (Alytidae) Peptides 30 2009 1069 1073
134. O. Cirioni, C. Silvestri, R. Ghiselli, F. Orlando, A. Riva, and E. Gabrielli Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis Crit Care Med 37 2009 1403 1407
135. J.P. Powers, and R.E. Hancock The relationship between peptide structure and antibacterial activity Peptides 24 2003 1681 1691
136. J.M. Saugar, M.J. Rodriguez-Hernandez, B.G. de la Torre, M.E. Pachon-Ibanez, M. Fernandez-Reyes, and D. Andreu Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action Antimicrob Agents Chemother 50 2006 1251 1256
137. M. Zasloff Antimicrobial peptides in health and disease N Engl J Med 347 2002 1199 1200
138. J.M. Conlon, E. Ahmed, T. Pal, and A. Sonnevend Potent and rapid bactericidal action of alyteserin-1c and its [E4K] analog against multidrug-resistant strains of Acinetobacter baumannii Peptides 31 2010 1806 1810
139. C.B. Park, H.S. Kim, and S.C. Kim Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions Biochem Biophys Res Commun 244 1998 253 257
140. M. Pazgier, D.M. Hoover, D. Yang, W. Lu, and J. Lubkowski Human β-defensins Cell Mol Life Sci 63 2006 1294 1313
141. J.G. Routsias, P. Karagounis, G. Parvulesku, N.J. Legakis, and A. Tsakris In vitro bactericidal activity of human β-defensin 2 against nosocomial strains Peptides 31 2010 1654 1660